1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position.
The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
Get alerted about grants like this
Save a search for “National Cancer Institute (NCI)” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
NOT-CA-25-020: Notice of Intent to Publish Funding Opportunity Announcement for NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32 - Independent Clinical Trial Required) Notice of Intent to Publish Funding Opportunity Announcement for NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32 - Independent Clinical Trial Required) Estimated Publication Date of Notice of Funding Opportunity : First Estimated Application Due Date: Earliest Estimated Award Date: Earliest Estimated Start Date: National Cancer Institute ( NCI ) The Center to Reduce Cancer Health Disparities (CRCHD) at NCI is planning to issue two new Notice of Funding Opportunity announcements (NOFO), the NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32), which will be published in two versions: Independent Clinical Trial Required and Independent Clinical Trial Not Allowed.
Beginning with the June 12, 2025, due date, the CURE ACE Award will support research training for early postdoctoral fellows in cancer research. The funding program aims to enhance the pool of qualified individuals for careers that have a significant impact on the health-related research needs of the Nation and enrich the scientific cancer research experience of trainees as they transition from pre-doctoral to post-doctoral training.
This Notice is being provided to allow sufficient time for applicants to develop strong applications. The NCI CURE ACE funding program supports post-doctoral training for candidates from diverse backgrounds in cancer research. It allows them to apply during the late pre-doctoral or early postdoctoral stages, even without preliminary data .
Applicants must identify a postdoctoral research mentor and establish a comprehensive research and training plan before or soon after beginning with the postdoctoral mentor. The program is open to pre- and post-doctoral scientists conducting research across all areas of cancer research.
Applicants must identify their postdoctoral mentor and submit their application through the institution where they plan to conduct their postdoctoral research.
The NCI CURE Academic Career Excellence (ACE) funding program supports early post-doctoral fellows from diverse backgrounds, including individuals from underrepresented backgrounds ( NOT-OD-20-031 ) who bring life experiences, geographic location, socioeconomic status, academic training, professional experience, disability status, military service, career stage, institutional affiliation, cultural background, and other factors that may contribute to unique perspectives to the research workforce, and who are committed to a career in basic biomedical, clinical, behavioral or Translational cancer research, including research on cancer health disparities.
Research Initiative Details For the purpose this funding program eligible candidates must be within 12 months prior to transitioning into a postdoctoral position or within the first two years of their postdoctoral research at the time of submission and/or resubmission of their application. By the time of the award, the applicant must be a U.S. Citizen or permanent resident.
The NCI CURE Academic Career Excellence (ACE) funding program provides for up to three years of support, offering a competitive salary and research funding support to retain the talents and enhance their training and development in cancer research. Importantly, receiving this award will not affect an applicants eligibility for other independent career development programs such as CURE K01, CURE K08, and CURE K22 programs.
Indeed, we believe this funding program will equip awardees with the necessary skills and experience to prepare more competitive applications in the future. Therefore, it is expected that awardees begin working on their individual career development applications (e.g. K01/K08/K22) once they secured K32 funding to maximize their potential for future funding.
As this is a pilot program, the number of awards will be determined based on the volume and quality of applications received. The Center to Reduce Cancer Health Disparities (CRCHD) at NCI is committed to fostering diversity in the cancer research workforce through this innovative funding opportunity.
Expected Number of Awards Primary Assistance Listing Number(s) Anticipated Eligible Organizations Public/State Controlled Institution of Higher Education Private Institution of Higher Education Nonprofit with 501(c)(3) IRS Status (Other than Institution of Higher Education) For-Profit Organization (Other than Small Business) Indian/Native American Tribal Government (Federally Recognized) Independent school districts Public housing authorities/Indian housing authorities Indian/Native American Tribally Designated Organization (Native American tribal organizations (other than Federally recognized tribal governments) U.S. Territory or Possession Indian/Native American Tribal Government (Other than Federally Recognized) Eligible Agencies of the Federal Government Applications are not being solicited at this time.
National Cancer Institute (NCI) The Center to Reduce Cancer Health Disparities (CRCHD) Weekly TOC for this Announcement NIH... Turning Discovery Into Health ®
Based on current listing details, eligibility includes: Within 12 months prior to transitioning into postdoctoral position or within first 2 years of postdoctoral research at submission. Must be U.S. Citizen or permanent resident by award time. Diverse backgrounds including underrepresented groups encouraged. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Varies Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is June 12, 2025. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
NIH NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) is a grant from the National Institutes of Health (NIH) / National Cancer Institute (NCI) that funds early-stage postdoctoral researchers in cancer-related fields to transition to independent research careers. The award provides a mentored phase (K99) followed by an independent phase (R00), supporting investigators who do not require an extended period of supervised training beyond their doctoral degrees. Eligible applicants must hold a research or clinical doctoral degree and be postdoctoral fellows who have not yet established independent research careers. The March 11, 2026 due date applies; award amounts vary by project.
Acceptability and feasibility of combination treatment for cervical precancer among South Africa women living with HIV is sponsored by National Cancer Institute (NCI) (via Univ Of North Carolina Chapel Hill). This R01 grant supports research exploring the acceptability and feasibility of a combination treatment for cervical precancer in South African women living with HIV. It aims to identify barriers and facilitators to treatment and conduct a feasibility trial of surgical excision followed by self-applied adjuvant 5-fluorouracil.
-Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop, standardize, and validate new and innovative assays, integrated strategies, or batteries of assays that determine or predict specific organ toxicities (e.g., ocular, dermal, hematotoxicity, cardiotoxicity, gastrointestinal toxicity, hepatotoxicity, nephrotoxicity, ototoxicity, olfactory loss, bladder toxicity, neurotoxicity, pulmonary toxicity, endocrine toxicity, and pancreatic beta cell toxicity), resulting from both acute and chronic exposures to various chemicals, environmental pollutants, biologics and therapeutic molecules or drugs. In addition, this FOA encourages the development, standardization, and validation of new models of arthritis, convulsion, infection and shock. New approaches for high throughput toxicity screening that involves the use of molecular endpoints, computer modeling, proteomics, genomics and epigenomics and the development of virtual tissues are also encouraged as are development of 3-dimensional organ models for toxicity evaluation. -Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-09-007, which encourages applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. Funding Opportunity Number: PA-09-006. Assistance Listing: 93.113,93.173,93.361,93.389,93.837,93.846,93.847,93.848,93.849,93.859,93.867. Funding Instrument: G. Category: ED,ENV,FN,HL.
Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), invites Small Business Innovation Research (SBIR) cooperative agreement applications from small business concerns (SBCs) that propose to develop new, or to improve existing application(s) of nanotechnology-based therapeutics or/and in vivo diagnostics. This FOA will specifically support pre-clinical optimization and testing of these cancer-relevant nanotechnology applications against the intended cancer type. The proposed projects must be milestone-driven and must be clearly directed toward development of an ultimate commercial product. The outcomes are expected to advance the discovery and pre-clinical optimization phase so that an Investigational New Drug (IND) or Investigational Device Exemptions (IDE) application could be submitted to the Food and Drug Administration (FDA) by the end or shortly after completion of the Phase II project period. To facilitate these steps, the NCI will assist the awardees in various ways, including the support through the NCI-sponsored Nanotechnology Characterization Laboratory. This FOA will NOT support basic research projects, studies on disease mechanisms, and clinical trials. Mechanism of Support. This FOA will utilize the SBIR (U43/U44) cooperative agreement mechanisms for Phase I and Phase II applications. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received. Funding Opportunity Number: PAR-10-286. Assistance Listing: 93.393,93.394,93.395,93.396. Funding Instrument: CA. Category: ED,HL. Award Amount: Up to $150K per award.
This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) for funding to perform research leading to the development of innovative technologies that may advance progress for early detection and assessment of individuals at risk and for early diagnosis, prognosis and follow-up of type 1 diabetes (T1D). Funding Opportunity Number: RFA-DK-15-024. Assistance Listing: 93.847. Funding Instrument: G. Category: FN,HL. Award Amount: $2M total program funding.